Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348806 | 0.83 | KDM4E (0.42) | KDM4EGPR183MEN1KMT2AHRH3 | |
| SCHEMBL11575106 | 0.83 | — | — | |
| SCHEMBL12850091 | 0.81 | KDM4E (0.37) | KDM4EGPR183MEN1KMT2AHRH3 | |
| SCHEMBL510209 | 0.79 | KDM4E (0.37) | KDM4EHRH3 | |
| SCHEMBL773035 | 0.78 | DAO (0.37) | KDM4EHRH3 | |
| SCHEMBL20021301 | 0.77 | PIK3CD (0.45) | KDM4EGPR183MEN1KMT2AHRH3 | |
| SCHEMBL10284004 | 0.77 | DRD2 (0.38) | KDM4EGPR183MEN1KMT2A | |
| SCHEMBL23944974 | 0.77 | OPRD1 (0.41) | GPR183MEN1KMT2A | |
| SCHEMBL689895 | 0.76 | KDM4E (0.40) | KDM4EGPR183MEN1KMT2AHRH3 | |
| SCHEMBL12396796 | 0.75 | KDM4E (0.39) | KDM4EGPR183MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | KDM4E 1270/4885GPR183 842/4885MEN1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.